Home > Oncology > ASCO 2020 > Breast & Ovarian Cancer > Combination pembrolizumab/chemo improves PFS in metastatic TNBC

Combination pembrolizumab/chemo improves PFS in metastatic TNBC

Presented By
Dr Javier Cortés & Catherine M. Kelly
ASCO 2020
Combining pembrolizumab with chemotherapy yielded a significant improvement in progression-free survival (PFS) compared with chemotherapy and placebo in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) that was PD-L1–positive, according to a randomized, phase III trial presented during the ASCO20 Virtual Scientific Program [1]. “Pembrolizumab monotherapy has shown antitumor activity and a manageable safety profile in patients with metastatic TNBC,” said Javier Cortés, MD, PhD, of the Vall d’Hebron Institute of Oncology, in Barcelona, who presented results of the KEYNOTE-355 trial. “The immunomodulatory properties of chemotherapy suggest that combining pembrolizumab with chemotherapy might enhance antitumor activity.” The new study included 847 patients randomly assigned to receive either pembrolizumab plus chemotherapy (investigator’s choice of nab-paclitaxel, paclitaxel, or gemcitab...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on